Monitoring & Labs

• Baseline: BMP (BUN/Cr), electrolytes, TSH, pregnancy test (if relevant), weight/BMI
• Level timing: 12‑h trough (or pre‑AM dose if BID)
• Level cadence: 5–7 days after dose change; then q3–6 months when stable
• Ongoing: Renal and thyroid function periodically; assess for toxicity signs
• Counsel: Hydration, salt intake consistency, DDI (NSAIDs/ACE‑I/diuretics)

Sources: FDA label; AGNP TDM consensus; local guidelines.

View lithium page →

• Baseline: LFTs, CBC with platelets, pregnancy test (if relevant), weight/BMI
• Level timing: 12‑h trough (ER may differ); target 50–125 µg/mL (clinical context)
• Ongoing: LFTs/CBC periodically; assess metabolic effects and sedation
• Precautions: Teratogenicity counseling; pancreatitis/hepatotoxicity warnings
• DDI: Enzyme interactions (UGT), lamotrigine titration adjustments

Sources: FDA label; AGNP TDM consensus; guideline statements.

View valproate page →

• Baseline: CBC (WBC/ANC), LFTs, sodium; consider HLA‑B*1502 in at-risk ancestry
• Ongoing: CBC/LFTs and sodium periodically; assess for rash and hyponatremia
• Levels: Consider trough levels in selected cases; strong CYP inducer → many DDIs
• Counsel: Contraception interactions; report rash/fever promptly

Sources: FDA label; guideline recommendations; pharmacogenetics advisories.

• ANC monitoring: Weekly ×6 mo → q2w ×6 mo → monthly thereafter (per current label)
• Metabolic: Weight/BMI, fasting lipids/glucose at baseline, 3 mo, then periodically
• Clinical: Monitor for infection; inflammation can raise levels; smoking lowers levels
• Early myocarditis vigilance: Follow local guidance (e.g., symptoms; some protocols include troponin/CRP early)

Sources: FDA/DailyMed labeling; consensus monitoring schedules.

View clozapine page →

• Baseline: Weight/BMI, waist circumference, blood pressure, fasting lipids & glucose/A1c
• Follow‑up: Weight/BMI q4–12 weeks during titration; fasting lipids & glucose/A1c at 3 months, then annually if stable
• EPS: Assess for parkinsonism/akathisia/tardive dyskinesia periodically
• QTc: ECG if risk factors or higher‑risk agents/combos
• Counsel: Lifestyle supports; metabolic risk discussion; DDIs that raise levels/QTc

Sources: Major guidelines; ADA/APA metabolic monitoring statements.

• EPS: Monitor periodically; consider prophylaxis only if indicated
• QTc: Caution; consider ECG if risk factors or higher doses
• LAI: Decanoate q4 weeks; follow product guidance for conversion

Sources: FDA/DailyMed label; guideline statements.

View haloperidol page →

• Intervals: Aripiprazole (q4–8wk), Paliperidone (q4–26wk variants), Risperidone (q2wk), Haloperidol (q4wk), Fluphenazine (q2–4wk), Olanzapine (q2–4wk)
• Oral overlap: Required for some LAIs (e.g., aripiprazole, risperidone); follow product‑specific guidance
• Sites: Deltoid or gluteal per product; rotate sites
• Observation: Olanzapine pamoate — post‑injection observation recommended in labeling
• Storage/handling: Per product; ensure proper reconstitution and needle size

Sources: FDA/DailyMed labeling; manufacturer administration guides.